The clinical course of symptomatic deep vein thrombosis after 3 months of anticoagulant therapy using fondaparinux/edoxaban or fondaparinux/vitamin K antagonist

BACKGROUND: For the management of venous thromboembolism (VTE), providing anticoagulant therapy within the therapeutic range has been a major challenge, as conventional therapy with unfractionated heparin (UFH) and vitamin K antagonist (VKA) requires frequent laboratory monitoring and dose adjustmen...

Descripción completa

Detalles Bibliográficos
Autores principales: Shimizu, Kazuhiro, Iiduka, Takuo, Sato, Shuji, Kiyokawa, Hajime, Nakagami, Takahiro, Mikamo, Hiroshi, Kawazoe, Masayo, Takahashi, Mao, Noro, Mahito
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2018
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5827747/
https://www.ncbi.nlm.nih.gov/pubmed/29503557
http://dx.doi.org/10.2147/TCRM.S153517

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5827747/
https://www.ncbi.nlm.nih.gov/pubmed/29503557
http://dx.doi.org/10.2147/TCRM.S153517

Ejemplares similares